

INDEX

ABSORPTION

- buccal, 29
- chewing tobacco, 281
- cigarette smoke, 29, 281
- lung, 29
- nicotine polacrilex gum, 281
- other tobacco exposure, 29
- smoking behavior, 153

ABSTINENCE

- (See also CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)
- aggression, 203
- spontaneous withdrawal assessment, 293
- weight gain, relapse predictor, 440
- withdrawal syndrome, reinforcement, 197

ACETYLCHOLINE

- desynchronization of electroencephalograms, 110
- high-affinity binding sites, 90, 92
- nicotinic cholinergic agonists, 81
- receptor measurement, 53
- release in cerebral cortex, 96
- turnover in hippocampus and frontal cortex, 98

ADDICTION

- definitions, 7, 149, 247-248, 249-250, 296
- effects of selected drugs, 299-303
- identification of hazardous drugs, 304
- nicotine and tobacco, 6, 8
- perceived functions of smoking, 397
- relationship to physical dependence, 296

ADOLESCENTS

- epidemiological studies, 261-262
- initiation of use, 259-265
- multidrug use, 259-265

ADOLESCENTS--Contd.

- negative- and positive-affect regulation, smoking, 399
- perceptions of stress, 121
- smoking prevalence, 573-577
- vulnerability factors, 266-267
- weight control and smoking, 438

ADVERTISING

- increased drug use, 305
- low-yield cigarettes, health risks, 566

AGE FACTORS

- body weight effects, 415, 416-418, 424, 431
- relapse, 316
- smoking cessation, 580-581
- smoking prevalence, 569, 579

ALCOHOL

- aversive stimuli, 280
- discriminative effects, 272
- multidrug use, 261-264
- place conditioning, 285
- prohibition and decreased use, 395
- reinforcement, 282

ALCOHOL CONSUMPTION

- abuse, smoking as risk factor, 401
- body weight, smokers vs. nonsmokers, 417-418, 431
- cigarette consumption effects, 167
- smoking prevalence among alcoholics, 402

ALKALOIDS, TOBACCO

- 2,3'-dipyridyl, structure, 27
- 6'-oxoanabasine, structure, 27
- anabaseine, structure, 27
- anabasine, structure, 27, 28
- anatabine, structure, 27, 28
- metanicotine, structure, 27
- myosmine, structure, 27, 28
- N-formyl-nornicotine, content, 28
- N'-methylanabasine, structure, 27
- N'-methylanatabine, structure, 27

INDEX

ALKALOIDS, TOBACCO--Contd.

N-nitrosonornicotine, structure, 27
nicotine N'-oxide, structure, 27
nicotyrine, structure, 27
nornicotine, structure, 27, 28
nomicotyrine, structure, 27
pharmacologic effects, 56
pseudoxynicotine, structure, 27

AMPHETAMINES

cigarette consumption effects, 167
discrimination, 172, 275-276

ANABASINE

content, 28
discrimination, nicotine-trained animals, 172
respiratory and cardiovascular effects, 57
structure, 27

ANTAGONISTS

mecamylamine, 484-485
naloxone-precipitated withdrawal syndrome, 297
nicotine effects in brain, reinforcement, 192
precipitated withdrawal syndrome, 293
pretreatment, smoke intake, 166

ANXIETY

consumption increases, 404
deprivation, 405
neuroticism and adult smoking habit, 402
pain thresholds, abstinence vs. high-nicotine cigarettes, 406-407
reduction, affect regulation, smoking, 396, 397
reduction, cognitive appraisal, 411-412
weight gain, smokers vs. nonsmokers and ex-smokers, 422
withdrawal symptom, 199, 201, 204
withdrawal symptom, with nicotine polacrilex gum, 208, 210

ARECOLINE

discriminative stimulus, 172, 175
hippocampal theta activity, 109

ATROPINE

discrimination, nicotine-trained animals, 174
effects on desynchronization, 109
effects on radioligand binding, 90

ATROPINE--Contd.

low dependence potential, 285

AUDITION

amplitude decreases, withdrawal symptom, 204
auditory evoked response during smoking abstinence, 202
information task, smoking effects, 385
psychological enhancement and sensory gratification, 413
vigilance tasks, smoking effects, 383

AUTONOMIC NERVOUS SYSTEM

myenteric plexus, 96
peripheral cholinergic neuron stimulation, 79
phasic increases, emotional stimulation, 411

AVERSIVE THERAPY

contingency contracting, 494-495
covert sensitization, 488
directed smoking, 488
less severe techniques, 492-493
rapid smoking, 501
relaxation training, 493-494
unpleasant conditions, 501

BEHAVIOR, ANIMAL

associated stimuli, 309
drug seeking, 309
food intake and body weight, nicotine administration, 434
negative-affect-reducing properties of nicotine, 407
physical activity, nicotine administration and cessation, 435
place preference or aversion, 194-195
reinforcing drug effects, 279
self-administration of drugs, 279

BEHAVIOR, HUMAN

classically conditioned, 307
cocaine deprivation, 310
compulsive drug use, 250
counseling, 502-503
drug seeking, 310
nicotine self-administration, negative reinforcement, 193-194
nicotine self-administration, response rates, 192
operant, 307

INDEX

BEHAVIOR, HUMAN--Contd.

- repetitive and stereotypic drug use, 8
- respondent, 307
- treatment strategies, 487-503

BELGIUM

- body weight, smokers vs. nonsmokers and ex-smokers, 419, 420

BIOASSAYS

- cotinine and nicotine, 42-43
- enzyme-linked immunosorbent assay, 43
- gas chromatography, 43
- mass spectrometry, 43
- radioimmunoassay, 43

BIOCHEMICAL MARKERS

- blood cotinine, 38, 42
- blood nicotine, 42
- carboxyhemoglobin, 42, 514
- cotinine, 515
- metabolism of nicotine, 41
- salivary cotinine levels, 42
- thiocyanate, 514-515
- urinary cotinine levels, 42

BLACK AMERICANS

- (See also ETHNIC GROUPS)
- cessation motivation and success, 510
- cessation of smoking, 508-509
- church and fraternal roles, 511-512
- coronary risk trial, 511
- health care access, 509
- physician influence, 511
- quit-smoking treatments, 511-512
- smoking and quitting patterns, 510
- social norms and advertising, 509-510
- sociodemographic factors, 509

BLOCKADE THERAPY

- mecamylamine, 484-485
- opioid dependence, 484
- tobacco dependence, 484-485

BLOOD

- carboxyhemoglobin, 39
- cotinine, 38
- nicotine, 30-33, 38-39
- pH and nicotine measures, 41
- wound healing, 600

BLOOD PRESSURE

- changes during abstinence or relapse, 202, 205

BLOOD PRESSURE--Contd.

- hypertension relationship to smoking, 600-601
- stress and nicotine, 409

BODY HEIGHT

- smokers vs. nonsmokers and ex-smokers, 416, 418

BODY TEMPERATURE

- changes, withdrawal symptom, 202
- skin, changes during abstinence or relapse, 202, 205

BODY WEIGHT

- adipose tissue, relative nicotine level, 32
- carbohydrate metabolism and smoking, 107
- changes during abstinence or relapse, 205
- control, smoking and nicotine effects, 381
- gains after nicotine cessation, animals, 432
- hypothalamic consummatory drive model, nicotine, 412-413
- nicotine administration, animals, with food intake, 434
- nicotine polacrilex gum, effects, 432
- smokers vs. nonsmokers and ex-smokers, 414-441
- smoking cessation effects, 199, 202, 439
- weight loss and nicotine, animals, 432

BRAIN

- alpha, beta, and theta power, with smoking, 111-112
- anteroventral thalamic nucleus, 86, 94
- blood-brain barrier, nicotine isothionium penetration, 57
- caudate nucleus, 94
- central grey matter, 86-87
- cerebellum, 94
- cerebral cortex, 94
- chemical mediation of nicotine, 8
- cortical arousal, withdrawal symptom, 202, 204
- cortical electric potentials, withdrawal symptom, 206
- cortical evoked potentials, withdrawal symptoms with nicotine polacrilex gum, 208

INDEX

BRAIN--Contd.

- dentate gyrus, 94
- electrocortical effects of nicotine, 107-112
- expectancy and orienting waves, 115
- frontoparietal cortex, 86-87
- glucose utilization, nicotine stimulation, 81, 86-88
- hippocampus, 94, 99-100, 109
- homovanillic acid levels after nicotine exposure, 110
- hypothalamus, 94, 97
- interanteromedial thalamic nucleus, 86
- interpeduncular nucleus, 86, 94, 95
- interpeduncular nucleus and medial habenula, ³H-labeled nicotine, 81
- lateral geniculate body, 86
- lateral habenulae, 86
- lateralized affective processors model, stressful conditions, 412
- locus coeruleus, 95
- medial habenulae, 86, 94, 95
- metabolism, binding sites, 85-86
- nerve cells, nicotine concentrations, 85
- nicotine concentrations, animals, 82-85
- nicotine levels, discrimination stimulus, 174
- nicotine polacrilex gum, 111-112
- nicotine-induced desynchronization, 109
- physiological effects of nicotine injections, 96-97
- presubiculum, 94
- putamen, 94
- rapid nicotine uptake, 32-33
- rat cerebellum, nicotine effects, 92-93
- relative nicotine level, 32
- retrosplenial cortex, 86
- substantia nigra pars compacta, 94
- superior colliculus, 86, 94
- ventral tegmental area, 86-88, 94

BUNGAROTOXIN

- binding sites, 47
- binding studies, mammalian brain, 91-94
- nicotinic cholinergic receptors, 88-89

BUNGAROTOXIN--Contd.

- receptor measurement, 53

CAFFEINE

- cigarette consumption effects, 167
- nonreinforcer, 281

CANADA

- body weight, smokers vs. nonsmokers and ex-smokers, 417

CARBON MONOXIDE

- carboxyhemoglobin content, 59
- smoking behavior, 154
- toxicity, 59
- visual information processing task, smoking effects, 384

CARBOXYHEMOGLOBIN

- carbon monoxide exposure, 59
- concentration, 39

CARCINOGENESIS

- benzo(a)pyrene-tetradecanoyl phorbol acetate, 604
- bladder, 604
- respiratory tract, 604
- tobacco cigarettes vs. nicotine polacrilex gum, 215

CARDIOVASCULAR SYSTEM

- (See also CORONARY HEART DISEASE)
- acute tolerance, 48, 49
- atherosclerosis, 596-598
- body weight, smokers vs. nonsmokers and ex-smokers, 417, 422, 427
- carbon monoxide effects, 596
- cardiomyopathy, 599-600
- contribution of nicotine, 56
- coronary artery disease, 598
- low-density lipoproteins, 596
- nicotine and carbon monoxide, 116-117
- nicotine effects, 596-601
- stress and smoking, 118
- Surgeon General's Report, 12
- thrombosis, 597-598
- very low-density lipoproteins, 596

CATECHOLAMINES

- amniotic fluid, 603
- nicotine effects on central neurons, 100
- release from extra-adrenal chromaffin tissues, 97-98

INDEX

CELLS

nerve, nicotine concentrations, 85

CENTRAL NERVOUS SYSTEM

nicotine concentrations, 83-84
nicotine isomethonium, 57
nicotinic cholinergic receptors, 89
pre- or postsynaptic release of acetylcholine, 95
psychoactive drugs, 267
tranquilization effects of nicotine, 409

CESSATION OF SMOKING

(*See also* ABSTINENCE; DEPRIVATION; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)

blacks vs. whites, 572
criteria, 516
heavy vs. light smokers, success rates, 577
males vs. females, 580, 581
measurements, 576, 580
men, neuroticism, 402
physical activity changes, 435
program development, nicotine addiction, 6
quit attempts, 150
quit difficulty and daily consumption, 206
quit ratios by age and sex, 1965 to 1985, 581
relapse and psychophysiological reactivity, 120
spontaneous remission, 255-269
stages, 518
Surgeon General's Report, 12
trials, 489-490
weight gain, 414, 416, 422, 423, 424, 425, 431, 439-440

CESSATION OF SMOKING,

METHODS

(*See also* NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT; TREATMENT)
acupuncture, 504
contingency contracting, 494-495
hypnosis, 504
nicotine addiction, 8-9
nicotine fading, 497-499
nicotine vapor inhaler, 212
self-efficacy, 497

CESSATION OF SMOKING, METHODS--Contd.

similarity to methods for other drugs, 467
stimulus control, 497

CHEMICAL DETECTION

biological samples, 256, 259
interpretation, 259
sensitivity, 259
specificity, 259

CHEMICAL STRUCTURE

nicotine, 27
nicotine metabolites, 35
tobacco alkaloids, minor, 27

CHEWING TOBACCO

nicotine absorption, 29, 31
nicotine levels, 38

CHILDREN

negative- and positive-affect regulation, smoking, 399
smoking and body weight beliefs, 438

CHOLINERGIC AGENTS

acetylcholine release, 81
interaction with biogenic amine pathways, 98
nicotine effects on central and peripheral nervous systems, 96-97

CIGAR SMOKING

body weight, smokers vs. nonsmokers, 417, 419
nicotine levels, 38
prevalence, men, 1964 to 1986, 580, 582
Surgeon General's Report, 12

CIGARETTES, HIGH-NICOTINE

affect modulation, 405
blood nicotine levels, 39
brand loyalty, 567
carboxyhemoglobin levels, 39
effects on recall, 389
emphysema, 604
knee-jerk reflex, 45
visual information processing task, smoking effects, 384
yields of nicotine, 26

CIGARETTES, HIGH-TAR

brand loyalty, 567
visual information processing task, smoking effects, 384

INDEX

CIGARETTES, HIGH-YIELD

carbon monoxide, 59
heart rate, partial tolerance, 55-56
smoking behavior, 163

CIGARETTES, LOW-NICOTINE

affect modulation, 405
effects on recall, 389
emphysema, 604
knee-jerk reflex, 45
Surgeon General's Report, 12
visual information processing task,
smoking effects, 384

CIGARETTES, LOW-TAR

Surgeon General's Report, 12
visual information processing task,
smoking effects, 384

CIGARETTES, LOW-YIELD

carbon monoxide, 59
consumption, health risks, 566
heart rate, partial tolerance, 55-56
vented, smoke concentration, 159-
161

COCAINE

cost, 283-284
crack, 281
increase in use, 305-306
multidrug use, 261-264
place conditioning, 285
starter drug, 278

COFFEE CONSUMPTION

smokers vs. nonsmokers, 437

COGNITION

concentration difficulty, withdrawal
symptom, 199, 201, 204, 205,
208, 210
euphoria and dysphoria, 117
oral contraceptive use, response to
stress, 118-119
stressor response among women,
118
task performance, 394

CONDITIONING

behavioral tolerance, 289
cues to smoke, 465
drug use as learned behavior, 307-
309
drug-opposite response, 289
nicotine addiction, 465
pharmacologic and psychological
factors, 465
physiological reactions, 466

CONDITIONING--Contd.

place preference and aversion, 194,
284
placebo effects, 309
taste aversion, 194

CONSUMPTION

adolescents, 260
adolescents, stress factor, 400
adults, effects of stress, 401
body weight effects, 415, 416, 417,
419, 420, 423, 426, 431
children, smoking and body weight
beliefs, 438
frequency and multiple drugs, 263-
264
heavy smokers, stress, 403
heavy vs. light smokers, smoking
cessation success, 577
high-yield cigarettes, 163
multiple drugs, 260
occasional tobacco use, 253-254
prediction, 262-263
progression of drug use, 261-263
race, age, and gender factors, 579
severity of withdrawal symptoms,
206
United States, 1973 to 1987, 567
United States, estimation through
taxes, 565
United States, per capita decline,
565-566

CONTROLLED SMOKING

compensatory behavior, 499-500
outcomes, 499-500
parameters, 499
prospects for abstinence, 500

COPING STRATEGIES

cognitive versus behavioral tech-
niques, 530-531
retrospective bias, 531
self-punitive cognitions, 531
short- and long-term effects, 496
skill-based treatment, 532
skills training, 496
stimulus control, 536-531
stress and smoking habit, 402
willpower, 531

CORONARY HEART DISEASE

(See also **CARDIOVASCULAR SYS-
TEM**)
ischemia, mortality
myocardial infarct, 593-599

INDEX

CORONARY HEART DISEASE-

- Contd.
- myocardial infarct, weight gain after smoking cessation or continuation, 426
- pharmacodynamic aspects, nicotine, 56
- risk, 598
- stress and smoking, 118
- Surgeon General's Report, 11

CORTICOSTEROIDS

- corticosterone and tolerance, 52
- plasma corticosterone levels, 100-101, 103
- plasma levels and cigarette smoking, 104-106

COST

- alternate nicotine delivery systems, 214
- individual and social, 252
- positive and negative incentives, 284
- required work, 283-284
- time, 283

COTININE

- bioassay comparison, 38-40
- biochemical detection, 515
- blood levels with nicotine polacrilex gum, withdrawal symptoms, 209
- content, 28
- daily cigarette consumption, 160
- discrimination, nicotine-trained animals, 172
- levels and severity of withdrawal symptoms, 206-207
- metabolites, 34
- nicotine metabolite, 34-38
- structure, 27
- tobacco-use marker, 38, 40

CRAVING

- abstinence, 205
- definitions, 295
- gender difference, 523
- measurement problems, 211
- mecamylamine effects, 485
- nicotine polacrilex gum, 208-209, 210, 475
- plasma nicotine levels, 211
- precipitating factors, 211
- recurrent and persistent, abstinence, 8
- relapse, 205, 523

CRAVING--Contd.

- sensory stimuli, 211
- smokeless tobacco withdrawal symptom, 207
- withdrawal symptom, 199, 201, 204

CYTISINE

- discrimination, nicotine-trained animals, 172-173
- respiratory and cardiovascular effects, 57

DEMOGRAPHIC FACTORS

- (See also SOCIOECONOMIC FACTORS)
- cigarettes and smokeless tobacco, 306
- marital status, 571
- smoking prevalence, 569, 571
- women and youth, 306

DENMARK

- body weight, smokers vs. nonsmokers and ex-smokers, 418

DEPENDENCE

- aversive limits, 268
- behavioral effects, 286
- cross-tolerance, 292
- definitions, 7, 198, 247-248, 245-250
- drug use, 12
- interoceptive drug effects, 268
- levels, 253
- neuroadaptation, 286
- physiological effects, 286
- positive reinforcement, 268
- potential testing, 269-270, 285-286
- progression, 253
- unconditioned stimuli, 268

DEPRESSION

- Navy men, cigarette consumption, 404
- nicotine polacrilex gum, 208-210
- withdrawal symptom, 201

DEPRIVATION

- (See also ABSTINENCE; CESSATION OF SMOKING; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)
- attention span of smokers, 386
- effects on memory, 388
- negative affect, 405, 406
- smoking rates and behavior, 164
- stress, relapse, 402

INDEX

DIAZEPAM

nicotine-induced antagonism, 175
withdrawal syndrome, 297

DIET

alkaline, smoking behavior, 163-164
changes during abstinence or relapse, 205, 206, 433-434
changes, smokeless tobacco withdrawal symptom, 207
food intake and appetite, withdrawal symptom, 202
food intake and smoking-related energy imbalance, 434
hunger, hypothalamic consummatory drive model, nicotine, 412-413
hunger, withdrawal symptom with nicotine polacrilex gum, 209, 210
sweet food intake and weight gain after smoking cessation, 433-434

DISCRIMINATION

behavior, 274
drug similarity, 274
generalization, 274
intravenous nicotine administration, humans, 176-177
metrazol, animals, 175
nicotine, administration method, animals, 171-172
nicotine, humans, 176-177
nicotine, pentolinium pretreatment, 176-177
nicotine vs. 3-methyl-pyridylpyrrolidine, 173
specificity, 275-276
testing, 274-277

DIZZINESS

acute sensitivity, 45, 47
tobacco poisoning, 595

DOPAMINE

control over acetylcholine turnover, 98
cue properties of nicotine, 97
nicotine agonists, 54
stimulation by nicotine, 54
turnover and release, 100-101

DOSE CONTROL

brand switching, 162
consistent nicotine intake, 158
function of time, 164
nicotine reinforcement, animals, 189-190

DOSE CONTROL--Contd.

ventilated cigarette holders, 159

DOSE-RESPONSE

amphetamines, 282
aversive limits, 282
biphasic effects, 44
compensatory nicotine intake, 283
heart rate changes, 56
psychoactivity, 272
self-administration and reinforcement, 282
self-reported effects, 274
titration-studies, nicotine, 282-283
tobacco smoke, 282
withdrawal reactions, 293

DRUG ABUSE

adolescents, smoking as risk factor, 400-401
liability factors, 304

DYSPHORIA

nicotine dose increases, 178

EDUCATION

high school dropouts, smoking prevalence, 574
smoking prevalence, 1985, 571

ELECTROENCEPHALOGRAPHY

activating effects of nicotine, 81-82
activity in rats, 52
changes during abstinence or relapse, 205, 206
distinct central nervous system effects, 108-109
history of nicotine studies, 108-109
nicotine-induced desynchronization, 112
parallels with self-reports, 274
power spectral analysis, 110
withdrawal symptoms with nicotine polacrilex gum, 208

ELIMINATION

acid loading, 40-41
alkaline loading, 40-41
kinetics, 38
measurement of smoke intake, 152
renal nicotine, 40-41
tolerance measure, 289
urinary tract, 33, 34, 36, 37

EMPHYSEMA

Surgeon General's Report, 11
weight gain, smokers vs. nonsmokers, 426

INDEX

ENDOCRINE

- adrenal cortex, 104-106
- follicle-stimulating hormone, 100-102
- growth hormone, 101
- luteinizing hormone, 100-102
- nicotine effects, 96
- prolactin, 100-102
- thyroid, 104
- thyroid-stimulating hormone, 100-102

ENVIRONMENTAL FACTORS

- conditioned responses, 306
- contingent reinforcement, 306
- drug costs, 306
- economic factors, 266
- individual reactions, 529
- negative affect, 530
- other smokers, 529-530
- parental drug use, 266
- peer smoking, 526
- place conditioning, 284-285
- relationship to direct drug effects, 308, 309
- smoking cues, 526, 529-530
- spousal smoking, 526-527
- stimulus control, 497
- stress, 530
- withdrawal effects, 204, 310-311

EPINEPHRINE

- levels during abstinence or relapse, 204, 205
- serum concentrations, 97

ETHNIC GROUPS

- (See also BLACK AMERICANS; HISPANIC AMERICANS)
- black Americans, 508-512
- black vs. white males, smoking prevalence, 569
- black vs. white pregnant smokers vs. nonsmokers, body weight, 418, 424
- blacks, smokers vs. nonsmokers and ex-smokers, body weight, 419
- blacks vs. whites, cigarette consumption, 577
- blacks vs. whites, smoking prevalence, 572, 579
- Hispanic Americans, 512-513
- Hispanic, smoking prevalence, 569-570
- Oriental alcoholism, 290

ETHNIC GROUPS--Contd.

- Oriental aversion to alcohol, 290

EX-SMOKERS

- body weight, vs. smokers and non-smokers, 416-430
- spontaneous remission, 466
- withdrawal symptoms, 199-200

EYES

- nicotine concentrations, 83
- pupil enlargement after nicotine use, 274
- pupillary constriction from opioids, 291
- visual evoked response during smoking abstinence, 202

FINLAND

- body weight, smokers vs. nonsmokers and ex-smokers, 429

FRANCE

- body weight, smokers vs. nonsmokers and ex-smokers, 422

GANGLIA

- localization of nicotine, animals, 85
- peripheral cholinergic neuron stimulation, 79

GASTROINTESTINAL SYSTEM

- heartburn, 607
- peptic ulcer, 605-607
- relative nicotine level, 32
- small bowel, nicotine reabsorption, 33
- stomach, nicotine concentrations, 82-83

GENETIC PREDISPOSITION

- adolescent drug use, 266-267
- vulnerability factors, 266

HAIR

- nicotine recovery, 33

HEADACHE

- acute sensitivity, 45, 47
- tobacco poisoning, 595

HEART

- acute nicotine tolerance, 48, 49
- arrhythmia, 599
- nicotine concentrations, animals, 84
- relative nicotine level, 32

HEART RATE

- abstinence or relapse, 122-123, 202, 204, 205, 206

INDEX

HEART RATE--Contd.

- acute tolerance, 48, 49
- drug and environmental effects, 308
- nicotine-induced tachycardia, 291
- smokeless tobacco withdrawal symptom, 207
- stress and nicotine, 409
- stress and smoking, 118
- tachycardia, 492-493
- withdrawal symptom, 199, 201
- withdrawal symptom with nicotine polacrilex gum, 210

HEROIN

- cigarette consumption effects, 167
- methadone effect, 288

HEXAMETHONIUM

- acetylcholine release blocked, 81
- attenuated amine release, 98
- discrimination, nicotine-trained animals, 174
- inhibiting effects on nicotine, 88, 92-93
- smoke-induced edema, 179

HISPANIC AMERICANS

- (See also ETHNIC GROUPS)
- gender difference, 512
- physician influence, 513
- prevalence of smoking, 512
- smoking cessation, 512-513
- smoking correlates, 512-513

HISTORICAL PERSPECTIVE

- addictive behavior, 269
- discovery of nicotine, 10
- medicinal vs. harmful effects, 9-10
- nicotine addiction, 10-11
- nicotine pharmacology, 10-11
- tobacco use, 9

HORMONES

- adrenocorticotropic, acetylcholine effects, 97
- adrenocorticotropic, nicotine effects, 100-103, 105-106
- androgen, testosterone levels, and smoking, 106
- arginine vasopressin, nicotine-induced release, 102-103
- estrogen production and metabolism, smoking effects, 106
- pro-opiomelanocortin, acetylcholine effects, 97

HORMONES--Contd.

- pro-opiomelanocortin, factors influencing release, 103-104
- prolactin, luteinizing, and follicle stimulating, 52

HYPOTHALAMUS

- consummatory drive model, nicotine, 412-413
- neuroendocrine function, 52

HYPOXEMIA

- fetal development, 603
- subsequent behavioral abnormalities, 603

IMPATIENCE

- nicotine polacrilex gum, 210
- withdrawal symptom, 199, 201

INHALATION PARAMETERS

- measurement techniques, 152
- published values, 156-157

INITIATION

- aversive reactions, 264-265
- dependence, cigarettes vs. nicotine polacrilex gum, 215
- drug classes, 259, 261-265
- environmental motivations, 278
- experimental use, 265
- smokeless tobacco, 265, 584
- social and pharmacologic factors, 264-265
- stress and early smoking onset, 399
- Surgeon General's Report, 12
- weight control and smoking, 438
- women, neuroticism, 402

INTEROCEPTIVE EFFECTS

- definition, 170
- dependence potential testing, 270-271
- mood and feeling, 270
- morning withdrawal cues, 307-308
- perception, smoke and nicotine, 179
- subjective pleasure, 308
- taste, airway irritation, 179

IRRITABILITY

- changes during abstinence or relapse, 205, 206
- nicotine polacrilex gum, 208, 210
- withdrawal symptom, 199, 201

JAPAN

- body weight, smokers vs. nonsmokers and ex-smokers, 420

INDEX

KIDNEYS

- nicotine concentrations, 82-84
- nicotine elimination, 33, 37
- relative nicotine level, 32

LEARNING

- behavioral tolerance, 289
- letter-digit substitution task, smoking effects, 386-387
- nicotine and smoking effects, humans and animals, 386
- paired-associated, smoking effects, 387, 388
- serial, retention, smoking effects, 388
- state-dependent, definition, 389
- verbal rote, smoking effects, 387-388

LIVER

- drug detoxification and tolerance, 290
- nicotine concentrations, 83-84
- nicotine metabolism, 37
- relative nicotine level, 32

LOBELINE

- discrimination, nicotine-trained animals, 173
- respiratory and cardiovascular effects, 57

LOCOMOTOR ACTIVITY

- decreases with nicotine, 49, 51
- nicotine induced, 53

LUNG DISEASES

- bronchoconstriction, 604
- cancer, Surgeon General's Report, 11
- chronic bronchial wall inflammation, 603
- emphysema, 603
- nicotine toxicity, 603-604
- pulmonary epithelial permeability, 604
- Surgeon General's Report, 12

LUNGS

- afferent neuron stimulation, 116
- nicotine concentrations, animals, 84
- relative nicotine level, 32

LYSERGIC ACID DIETHYLAMIDE

- (LSD)
- nonreinforcer, 281, 282, 285

MAINTENANCE OF SMOKING

- Surgeon General's Report, 12

MAINTENANCE OF SMOKING--Contd.

- weight control, 438

MARIJUANA SMOKING

- cigarette consumption effects, 168
- multidrug use, 261-264
- smoking as risk factor, 401

MECAMYLAMINE

- brain and spinal cord effects, 89
- discrimination, nicotine-trained animals, 173-174
- dose-response, 93
- effects on desynchronization, 109
- local cerebral glucose utilization, **86-88**
- nicotine conditioning taste aversion, 196
- nicotine-induced antagonism, 175
- nicotinic receptors blocked, 81
- place preference, nicotine effects, 195
- pretreatment, effect on conditioned reinforcer, 191
- pretreatment, harshness ratings of smoke, 179
- pretreatment, negative nicotine reinforcement, 193
- pretreatment, nicotine discrimination, 176-177
- pretreatment, nicotine polacrilex gum, discrimination, 178
- pretreatment, smoke intake, 166

MEMORY

- (See also RECALL)
- delayed, smoking effects, 388
- immediate, smoking effects, 388
- nicotine and smoking effects, humans and animals, 386
- recognition study, state-dependent, 390
- task performance, 394
- verbal, smoking and nicotine effects, 389
- words and order, smoking effects, 389

METABOLISM

- (See also PHYSICAL ACTIVITY)
- animal, body weight, smoke exposure or nicotine administration, 436
- body weight and smoking, 434, 435-437

INDEX

METABOLISM--Contd.

- decreased, withdrawal symptom, 203
- nicotine clearance, 40
- nicotine metabolites, 34, 35, 36
- rate, 37
- smokers vs. nonsmokers, 53
- smoking cessation effects, 433, 436

METHADONE

- cigarette consumption effects, 167
- effect on heroin use, 288
- efficacy, 296

MOOD

- changes during abstinence or relapse, 205-206
- hedonic systems model, negative affect, 411
- regulation, smoking and drug use, 401
- regulation, subjective well-being, smoking effects, 394-399

MORPHINE

- discrimination, 275-276
- euphoria and self-administration, 277
- physical dependence, withdrawal, 294
- place conditioning, 285

MOTIVATION

- behavioral tolerance, 289
- gender differences, 506
- self-perceived reasons for smoking, 398
- treatment enhancement, 332-334

MOTOR BEHAVIOR

- alcohol-induced muscle relaxation, 291
- smoking and nicotine effects, 392-393
- task performance, 394

MUCOUS MEMBRANES

- cardiovascular effects of nicotine, 598

MUSCLES

- alcohol-induced relaxation, 291
- N-methylnicotinium ion, pressor and neuromuscular effects, 57
- relative nicotine level, 32
- tonic and phasic muscular activity, nicotine effects, 410

MUTAGENESIS

- Salmonella typhimurium* Assays, 605

NALOXONE

- cigarette consumption effects, 168
- opioid withdrawal, 297

NAUSEA

- acute sensitivity, 45, 47
- tobacco poisoning, 595

THE NETHERLANDS

- body weight, smokers vs. nonsmokers and ex-smokers, 430

NEUROENDOCRINE FUNCTION

- nicotine effects, 95-96

NEW YORK

- smokeless tobacco use, 1986, 581

NEW ZEALAND

- body weight, smokers vs. nonsmokers and ex-smokers, 421

NICOTINE

- content, different tobaccos, 28
- intake, 40
- place conditioning, 285
- sensitivity, 46-47
- structure, 27

NICOTINE AEROSOLS

- respiratory sensations, plasma nicotine levels, 179-180
- tobacco-like sensations, cessation method, 180

NICOTINE CONTENT

- cigarettes vs. chewing tobacco, snuff, 28
- high-yield cigarettes, 26
- low-yield cigarettes, 26

NICOTINE DELIVERY, ALTERNATE

- (See also CESSATION OF SMOKING, METHODS, NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT; TREATMENT)
- chewable product, FDA ruling, 212-213
- dependence potential, 214
- nicotine polacrilex gum, dependence and withdrawal, 207-208
- potential for abuse with concurrent tobacco use, 213-214
- tobacco cigarettes vs. nicotine polacrilex gum, 215

INDEX

NICOTINE DELIVERY,

ALTERNATE--Contd.

- tolerance, physical dependence, withdrawal symptom alleviation, 212
- toothpaste-like formulation, FDA review, 212
- toxic effects, convenience, dependence potential, 213

NICOTINE FADING

- combination with self-monitoring, 498
- definition, 497
- low-tar and -nicotine brands, 497-498
- outcomes, 498-499

NICOTINE METABOLISM

- nicotine-1'-N-oxide, 36
- pathways, 34-37
- tachyphylaxis, 50

NICOTINE PHARMACOLOGY

- addictive properties, 6
- discrimination effects, 272
- pharmacokinetics, 25, 32
- stimulant and depressant effects, 79
- tobacco cigarettes vs. nicotine polacrilex gum, 215

NICOTINE POLACRILEX GUM

(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE REPLACEMENT; TREATMENT)

- absorption, 29, 31
- affect modulation, 405
- blood levels of nicotine, 472
- body weight effects, 432
- combined with behavioral therapy, 476
- coronary heart disease, 599
- craving reduction, 475
- dose-patient relationship, 478-479
- duration of use, 478
- efficacy trials, 473-474, 475-478, 486
- fetal development, 602-603
- followup, 477
- mood regulation during smoking cessation, 406
- physical dependence, 210
- physician trials, 476-477
- poststimulus components, 115

NICOTINE POLACRILEX GUM--

Contd.

- pretreatment, smoking behavior, 165
- relapse, 477-478
- safety vs. cigarettes, 214-215
- stimulus effects, 178
- temporary treatment aid, 214
- toxicity, 213
- weight gain, 423
- withdrawal symptom alleviation, 207, 208, 472

NICOTINE REPLACEMENT

(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; TREATMENT)

- addiction treatment, 7
- aerosols, 480
- comparisons of preparations, 480-481
- dependence, 481
- forms and rationale, 471
- nasal solutions, 479
- polacrilex gum, 471-479
- side effects, 480
- transdermal patches, 479-480

NITROSAMINES

- American snuff, 605
- chemical structure, 606
- mainstream tobacco smoke, 605

NOREPINEPHRINE

- levels during abstinence or relapse, 205
- neuroendocrine activity, 101
- nicotine effects, 100-101
- release in hypothalamus, 97

NORNICOTINE

- content, 28
- discrimination, nicotine-trained animals, 172
- structure, 27

NORWAY

- body weight, smokers vs. nonsmokers and ex-smokers, 417, 418, 421, 426

OCCUPATIONS

- asbestos workers, 422
- civil servants, 422
- factory workers, 419
- farm workers, 594

INDEX

OCCUPATIONS--Contd.

government workers, 418
insurance company employees, 416
manufacturing company employees,
419
nurses, 439
physicians, 438
steel workers, 419
telephone company employees,
420, 423

OPIOIDS

addiction, 247
addictive patterns, 282
chipping, 253
discriminative effects, 272
fetal syndrome, 251-252
physical dependence potential, 286-
287
protracted withdrawal, 253
tolerance, 287
withdrawal, 291-294

OXOTREMORINE

discrimination, nicotine-trained ani-
mals, 172
muscarinic cholinergic agonist, 52

PANCREAS

body weight and smoking, 107

PASSIVE SMOKING

Surgeon General's Report, 12

PEER GROUPS

relapse, 321-322
treatment, 334

PENTOBARBITAL

depressant, cigarette consumption
effects, 167
discrimination, 275-276

PERFORMANCE

impairment, withdrawal symptom,
204, 205, 206
nicotine polacrilex gum, 203, 208
problem solving, attention, and
memory, 391

PERIPHERAL EFFECTS OF NIC- OTINE

discriminative stimulus, 173
overview, 79

PHARMACODYNAMICS

cardiovascular changes, 55-56
daily smoking patterns, 55
definition, 25
dose-response, 44

PHARMACODYNAMICS--Contd.

tolerance, 44-46

PHARMACOLOGIC TREATMENT

alprazolam, 482
blockade therapy, 328
clonidine, 328-329, 482-483
deterrents, 329
drug replacement therapy, 326-328
mood changes, 483-484
relief from withdrawal symptoms,
327
symptomatic treatment, 328, 481-
483

PHYSICAL ACTIVITY

(See also METABOLISM)
body weight differences, smokers
vs. nonsmokers, 434
body weight, smoking cessation,
435
decreased energy expenditure, with-
drawal symptom, 203
exercise tolerance, 600
smokers vs. nonsmokers, 435

PIPE SMOKING

body weight, smokers vs. nonsmok-
ers, 417, 419
coronary heart disease, 598
nicotine levels, 38
prevalence, men, 1964 to 1986, 580,
582
Surgeon General's Report, 12

POLAND

body weight, smokers vs. nonsmok-
ers and ex-smokers, 420

POLYDRUG DEPENDENCE

adolescents, 259-266
frequency of use, 263-264
initiation of cigarette and other
drug use, 259-269
prediction, 262-263
preference tests, 272-273
progression of use, 261-263
tobacco-opioids-alcohol-stimulants,
254

POTENTIALS, SENSORY EVENT- RELATED

auditory function and nicotine,
112-113
contingent negative variation, 114-
115

INDEX

POTENTIALS, SENSORY EVENT-RELATED--Contd.

visual function and nicotine, 113-114

PREGNANCY

amniotic fluid, nicotine recovery, 33
body weight, smokers vs. nonsmokers, 416, 418, 424, 426, 429
breast-milk fluid, nicotine levels, 33
low birth weight, 602
nicotine effects on animals, 602
perinatal mortality, 602
placenta, carbon monoxide and nicotine, 602
placenta, nicotine penetration, 33
prematurity, 602
spontaneous abortion, 602

PRETREATMENT

lidocaine, airway sensations, 169
nicotine, smoking behavior, 165-166
pentolinium, nicotine discrimination, 176-177
pimozide, taste aversion, 196

PREVENTION OF SMOKING

aversive smoking, 501-502
program development, nicotine addiction, 6
skills training, 501

PSEUDOOXYNICOTINE

structure, 27

PSYCHIATRIC DISORDERS

multiple diagnosis, 254
negative affect of smoking, 403
neuroticism, 401-402
tobacco-nicotine dependence and withdrawal, 12

PSYCHOACTIVITY

drug classification, 269-270
interoceptive effects, 270
mood and feeling, 270-271
tobacco cigarettes vs. nicotine polacrilex gum, 215

PSYCHOMOTOR PERFORMANCE

letter crossing tests, smoking effects, 384
smoking abstinence vs. nicotine polacrilex gum, 203
smoking and nicotine effects, 381
smoking effects, methodological limitations, 382

PSYCHOMOTOR PERFORMANCE--

Contd.

Stroop test, nicotine effects, 385-386

sustained attention tasks, definition, 382

PUFFING PARAMETERS

definitions, 153
frequency, duration, volume, inter-puff interval, 153-154
interdependent relationships among measures, 153
measurement techniques, 151-152
published values, 156-157
visual information processing, smoking effects, 384
within-cigarette changes, nicotine dose, 155-158

RAPID SMOKING

aversive smoking cessation therapy, 196-197
cardiovascular and pulmonary risks, 493
comparison with other techniques, 492-493
conditioned aversive response, 492
rapid puffing, 501-503
single and multicomponent procedures, 491-492
stress, 494
tachycardia, 492-493

REACTION TIME

simple and complex, smoking effects, 392-393
smoking abstinence vs. nicotine polacrilex gum, 203
visual and auditory, smoking effects, 385
visual information processing, smoking effects, 384
visual, smoking effects, 383

RECALL

(See also MEMORY)
immediate, nicotine effects, 388
short- and long-term, nicotine tablets, 390
state-dependent, smoking vs. no-smoking conditions, 390
verbal rote learning, smoking effects, 387-388

RECEPTORS

adaptation to drug, 289
binding sites, minor alkaloids, 56

INDEX

RECEPTORS--Contd.

- constitutional tolerance, 290
- dihydro-beta-erythroidine, rat brain, 91
- disulfoton, ³H-nicotine binding, 54
- functional or pharmacodynamic tolerance, 289

RECEPTORS, CHOLINERGIC

- distribution of ³H-acetylcholine and ³H-nicotine, 80
- neuron stimulation, 79
- regulation of ³H-nicotine sites in mice, 80

RECEPTORS, NICOTINIC

- aversive effects of nicotine injections, 193
- binding sites, 53
- chronic tolerance, 53
- ganglionic and neuromuscular types, 88-89
- high-affinity sites, 90, 92-94
- locomotor activity, 53
- low-affinity sites, 90-91
- peripheral nervous system, 88-89
- primary and secondary binding sites, 86
- radioligand binding studies, 89-92
- tolerance, 54

REINFORCEMENT

- evaluation, 279-281
- negative, behavior modification, 193
- negative, nicotine injection, 193
- nicotine addiction, 6
- positive, continuous, intravenous nicotine, 182
- positive, intermittent, intravenous nicotine, 189, 190-191
- positive, nicotine, review, 183-188
- potential of various drugs, 305
- self-administration, 276-279
- stimulus effects, 268
- tobacco cigarettes vs. nicotine polacrilex gum, 215

REINFORCERS

- cocaine vs. nicotine, 189-190
- definition, 170
- positive, biobehavioral mechanism, dependence-producing drugs, 181-182
- psychoactive drugs, 8

RELAPSE

- (See *also* SPONTANEOUS REMISSION)
- abstinence violation effect, 532
- age factors, 316
- alcohol and opioid dependencies, 316
- attribution theory, 525-526
- biochemical detection, 313
- correlates, 315, 317-319
- definition, 312, 518
- demographics, 520
- drug dependence severity, 315-316
- drug use, 8
- family support, 321, 324
- frequency of smoking, 521
- gender differences, 520
- high-risk factors, 519, 529-530
- long-term abstinence difficulties, 311
- measurement, 313
- negative emotions, 322-324
- peer drug use, 321-322
- prevention skills, 330-331
- psychiatric impairment, 316
- quitting history, 312, 522
- rates by drug class, 313-314
- self-efficacy, 524-525
- sensory cues, 121-123
- smoking history, 521
- social learning theory, 519
- treatment effectiveness, 315, 320-321
- treatment modalities, 312-313
- typologies, 521-522
- weight gain, risk factor, 440, 523-524
- withdrawal and dependence, 522-523
- withdrawal symptom alleviation, 205
- work and leisure activities, 322, 324

RESEARCH METHODS

- biochemical markers, 514-515
- carbon monoxide, 514
- carboxyhemoglobin, 514
- confounding design factors, 119-120
- cotinine assays, 515
- nicotine dosage control, 119
- self-reports, 515
- study design, 513-514
- suspect data, 514

INDEX

BESTLESSNESS

- changes during abstinence or relapse, 205
- nicotine polacrilex gum, 208, 210
- withdrawal symptom, 199, 201

ROLL-YOUR-OWN

- prevalence, men, 1964 to 1986, 580, 582

SALIVA

- nicotine secretion, 33
- tobacco poisoning, 595

SATIATION

- comparison with comprehensive procedure, 501-502
- single and multicomponent procedures, 488, 491

SELF-ADMINISTRATION

- abstinence symptoms, 310
- adjunctive, schedule-induced behavior, 278-279
- alcohol, 278, 281
- amphetamine, 278, 281
- animal research methods, 279-280
- behavioral process, 158
- cocaine, 278-281
- compulsive use, 149
- drive state, 277
- drug substitution, 278
- environmental pressure, 278
- free sampling, 277
- graduation, 277-278
- human and animal studies, 276-277
- human research methods, 280-281
- initiation, 277
- intravenous nicotine, response rates, humans, 192
- morphine, 278, 281
- nicotine, 278-281
- pentobarbital, 278, 281
- positive reinforcement, 276-277, 279
- reinforcing effects, 279-280
- reinitiation of drug use, 310
- voluntary conditions, 279

SENSATION

- environmental stimulus, conditioned reinforcers, 191
- place conditioning, 284
- psychological enhancement and sensory gratification, 413

SEROTONIN

- interneuronal communication system, 98
- pharmacological effects of nicotine, 99-100

SEX RATIO

- adolescents, weight control and smoking, 438
- body weight, smokers vs. nonsmokers, 415, 417, 421, 431
- cessation and relapse rates, 505-508
- education, 506-507
- heavy vs. light smokers, 577
- high school seniors, smoking prevalence, 574-576
- Hispanics, smoking prevalence, 569-570
- motivation to quit, 506
- neuroticism and adult smoking habit, 402
- smokeless tobacco use, 1970 to 1986, 580, 583
- smoking cessation rates, 580, 581
- smoking prevalence, 569, 572, 573, 579
- social support, 508
- social values and beliefs, 507
- stress and smoking, 118, 508
- weight gain after smoking cessation, 416, 433, 507-508

SLEEP

- disturbances, nicotine polacrilex gum, 208, 210
- disturbances, smokeless tobacco withdrawal symptom, 207
- disturbances, withdrawal symptom, 202, 204, 205, 206

SMELL

- aversion to alcohol, 280
- environmental stimulus, conditioned reinforcers, 191
- receptors, 58-59
- tobacco grade and type, 58-59
- tobacco smoke, place conditioning, 285

SMOKE CONSTITUENTS

- acetaldehyde effects, 60
- benzo(a)pyrene, 604
- brand switching, 162
- nonnicotine, tracheobronchial sensations, 168-169

INDEX

- SMOKE INHALATION, ANIMAL**
lungs, spleen, intestine, and brain,
nicotine concentrations, 84
- SMOKELESS TOBACCO**
(*See also* SNUFF)
addiction, with nicotine, 13
demographic changes, 306
nicotine dependence, 214
starter products, 265
withdrawal symptoms, 207
- SMOKELESS TOBACCO USE**
gum and mouth diseases and neo-
plasms, 213
prevalence, 1970 to 1986, 580, 583
- SMOKING ANTECEDENTS**
anxious, aggressive, and neurotic
personality traits, 402
personality measures, 402
stress, adolescents, 400
- SMOKING ARTICLES**
ventilated cigarette holders, 159
- SMOKING BEHAVIOR**
biochemical and behavioral mea-
sures, 154
carbon monoxide intake, 154
cigarette length, 161
consistent patterns, 155
measurement techniques, 150-152
perceived functions of smoking, 397
Surgeon General's Report, 12
switching cigarette brands, 161-162
taste and smell, 58-59
- SMOKING CONTROL PROGRAMS**
multicomponent, smoking cessation,
501-503
Surgeon General's Report, 12
- SMOKING HABIT**
negative- and positive affect regula-
tion, 399
smoking-related disease diagnosis,
150
United States, adults, prevalence,
565-567
young adults, prevalence and con-
sumption, 578
- SMOKING SURVEYS**
adolescents, 573-577
Adult Use of Tobacco Survey, 572
Behavioral Risk Factor Surveil-
lance System, 573
Current Population Survey, 573
- SMOKING SURVEY--Contd.**
Hispanic Health and Nutrition Ex-
amination Survey, 569-570
National Health Interview Surveys,
565-566, 568-569, 572
self-reported smoking status, un-
derreporting, 567-568
tobacco use trends, 9
- SNUFF**
(*See also* SMOKELESS TOBACCO)
angina pectoris, 600
dipping prevalence, 1970 to 1986,
580, 583
nicotine absorption, 29-31
nicotine levels, 38
paroxysmal hypertension, 600
- SOCIAL SUPPORT**
buddy system, 495
gender differences, 508
global support, 527
partner support, 527-528
smoking cessation, 526-527
spouse, 495
- SOCIOECONOMIC FACTORS**
(*See also* DEMOGRAPHIC FAC-
TORS)
body weight, smokers vs. nonsmok-
ers, 420, 428
ethnic, class, gender differences,
505
smoking prevalence, 1985, 571
treatment and prevalence, 467
- SPONTANEOUS REMISSION**
(*See also* RELAPSE)
comparison by drug class, 255-259
contributing factors, 255-259
studies, 257-258
- STATE-DEPENDENT LEARNING**
abstinence vs. smoking, 393-394
definition, nicotine, humans, 181,
389
nicotine effects, 387
- STATISTICAL ANALYSIS**
Addiction Research Center Invento-
ry, 271-272
discrimination procedures, 271
Morphine Bazedrine Group scale,
271-273
overlap of drug classes, 271
- STIMULANTS**
addiction, 247

INDEX

STIMULANTS--Contd.

- addictive patterns, 282
- discriminative effects, 272
- nicotine, 177

STRESS

- abstaining and coping, 528-529
- adult cigarette consumption, 401
- affect modulation, smoking and nicotine effects, 405-408
- affect regulation, smoking, 395-399
- consumption increases, 404
- elimination of nicotine, 41
- Hassles Scale, 528
- hedonic systems model, negative affect, 411
- initiation and consumption risk, 413-414
- lateralized affective processors model, 412
- low- vs. high-nicotine cigarettes, 405
- management skills, 332
- Navy men, smoking habit, 403-404
- nicotine polacrilex gum, 405
- nicotine withdrawal, conditioned responses, 408
- nurses, smoking habit, 403
- perceived stress, 528
- perceptual and pain-endurance thresholds, nicotine effects, 410
- psychophysiological reactivity, 117-122
- reduction, gender differences, 508, 528
- reduction, neurochemical role of nicotine, 408-409
- reduction, smokers vs. nonsmokers, 407
- relationship to relapse, 528-529
- risk factor for adolescent smoking, 399-401
- smoking and nicotine effects, 381
- smoking cessation relapse, 402, 528
- subjective well-being, smoking effects, 394-395

STUDENTS

- high school boys, body weight and smoking, 438
- high school seniors, smoking prevalence, 574-576
- junior and senior high school, stress and smoking initiation, 400

SWEDEN

- body weight, smokers vs. nonsmokers and ex-smokers, 428

SYMPATHETIC NERVOUS SYSTEM

- arousal regulation with nicotine, 409

TAR CONTENT

- sales-weighted average yield, 566
- smoking maintenance, 58
- tobacco taste characteristics, 58

TASTE

- environmental stimulus, conditioned reinforcers, 191
- first cigarette of day, 47
- menthol popularity among black Americans, 510
- receptors, 58
- tobacco cigarettes vs. nicotine polacrilex gum, 215
- tobacco grade and type, 58
- tobacco smoke, place conditioning, 285

TASTE AVERSION

- alcohol, 280
- apomorphine vs. nicotine, 196
- chlorisondomine, 196
- nicotine conditioning, animals, 195-196

TAXATION

- reflection of cigarette consumption, 565

TERATOGENICITY

- animals, 601
- humans, 601-602

THERAPY

- approved drug uses, 298
- deterrent, silver acetate, 485-486
- replacement, 326-328
- symptomatic, 328

TOBACCO CONSTITUENTS

- beta-carbolines, pharmacologic effects, 60

TOBACCO SUBSTITUTES

- smoke condensate, sensory effects, 169

TOLERANCE

- acquired reaction, 289
- acute, tachyphylaxis, 44, 47-50
- animal and human studies, 251

INDEX

TOLERANCE-Contd.

- behavioral, 44
- behavioral and physiological responses to nicotine, 197
- chronic, 44, 50-54
- constitutional reaction, 290
- cross-tolerance, 288, 292
- dependence potential testing, 286
- dose escalation, 50, 51
- intoxication, 251
- limits on escalation, 286-287
- measures, 288
- mechanisms, 288-296
- nicotine addiction, 6
- nicotine uptake, 8
- pharmacodynamic, functional, 44
- pharmacokinetic, dispositional, 44
- toxic effects, 45

TOXICITY

- acute, 593-596
- acute sensitivity, 45, 46
- children, 595
- chronic, 596
- nicotine polacrilex gum, 595-596
- physiological and psychological, 252

TREATMENT

- (See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT)
- abstinence maintenance, 503
- behavioral strategies, 329-334
- blockade therapy, 328
- clonidine, 328-329
- family support, 333
- goals, 325
- leisure activity skills, 331-332
- loss of control, 325
- methodology, 513-516
- motivation enhancement, 332-334
- nicotine polacrilex gum, maintaining physical dependence, 210
- overview, 465-470
- peer support, 334
- pharmacologic approaches, 326-329
- professional contact, 333
- relapse prevention skills, 330-331
- relief from withdrawal symptoms, 327
- replacement therapy, 326-328
- stress management skills, 332
- symptomatic therapy, 328

TREMOR

- hand, changes during abstinence or relapse, 205
- smoking effects, 392

TWINS

- body weight, smokers vs. nonsmokers, 417

TYROSINE HYDROXYLASE INHIBITOR

- histofluorescence studies, 100

UNITED KINGDOM

- Wales, body weight, smokers vs. nonsmokers and ex-smokers, 416

URINE

- acidification and cigarette consumption, 163
- cotinine, 36, 37
- nicotine isomethonium, 57
- nicotine-N-oxide, 36, 37
- pH and stress, 41
- unchanged nicotine content, 33

VISION

- conditioned reinforcer, nicotine delivery, 191
- environmental stimulus, 191
- information processing task, smoking effects, 384
- peripheral vision monitoring, smoking effects, 385
- place conditioning, tobacco smoke, 285
- psychological enhancement and sensory gratification, 413
- rapid visual information task, smoking effects, 385
- vigilance tasks, nicotine tablet effects, 383
- vigilance tasks, smoking effects, 383

WEST VIRGINIA

- smokeless tobacco use, 1986, 581

WITHDRAWAL SYMPTOMS

- (See also ABSTINENCE; CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYNDROME)
- aggression, 203
- anxiety, 199, 201, 204, 208, 210
- behavioral and physiological sequelae, 251
- biting, animals, 204-205

INDEX

WITHDRAWAL SYMPTOMS--Contd.

body temperature changes, 202
concentration difficulty, 199, 201, 204, 205, 208, 210
conditioned drug seeking, 310
craving, 199, 201, 204, 208-209, 210
depression, 201, 208-210
electroencephalography changes, 208
environmental and pharmacologic factors, 198
environmental stimuli, 310
fatigue, 201, 202, 205
further drug intake, 8
hearing amplitude decreases, 204
hunger, food intake, 202, 207, 209, 210, 412-413, 434
hypothalamic consummatory drive model, nicotine, 412-413
identified, 198-199
increased heart rate, 210
irritability, impatience, 199, 201, 208, 210
measurements and techniques, 199-200
metabolism changes, 203, 433, 436
negative affect reduction, nicotine, 408
nervousness, 199, 201
nicotine blood levels with nicotine polacrilex gum, 209
nicotine polacrilex gum, 207, 208, 472
opioids, 291, 292
performance, 208
physical complaints, 199, 201, 208
plasma nicotine levels and symptom severity, 206-207
rebound phenomena, 204
respiration rate decrease, 202
restlessness, 199, 201, 208, 210
sleep disturbances, 202, 204, 205, 206, 207, 208
stress, 402, 408, 528, 529

WITHDRAWAL SYMPTOMS--Contd.

tobacco cigarettes vs. nicotine polacrilex gum, 215
weight gain, 414, 416, 422, 423, 424, 425, 431, 438, 439-440, 523

WITHDRAWAL SYNDROME

(*See also* ABSTINENCE; CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYMPTOMS)

American Psychiatric Association, recognition, 295
autonomic measures, 291
behavioral, 291
dependence potential testing, 286
distinctive signs, 296-297
evidence of addiction, 6, 294-295
precipitated responses, 293
protracted, 253
somatomotor measures, 291
spontaneous reactions, opioids and depressants, 292
variability, 294-295

WOMEN

black, smoking prevalence, 569
body weight, smokers vs. nonsmokers, 420
education, 506-507
electroencephalograms of neonates from smokers, 112
prolactin and breast feeding, smoking effects, 102
smoking prevalence, 569
social factors, 507-508
stress and smoking, 400, 508
Surgeon General's Report, 12
treatment programs, 467
weight control, 439, 507-508
weight gain, 523

WORKPLACE

Surgeon General's Report, 12

YUGOSLAVIA

body weight, smokers vs. nonsmokers and ex-smokers, 425